Search Results

You are looking at 101 - 110 of 149 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

Next-Generation Cancer Vaccine Approaches: Integrating Lessons Learned From Current Successes With Promising Biotechnologic Advances

Dung T. Le and Elizabeth M. Jaffee

-Tricom vaccine, which expresses transgenes for prostate-specific antigen (PSA) and costimulatory molecules (B7.1, ICAM-1, and Lfa-3). 15 With chemotherapy, tumors can regress, but once resistance develops, the growth rate returns to baseline. For the PSA

Full access

Gleason Scoring at a Comprehensive Cancer Center: What’s The Difference?

Natasha C. Townsend, Karen Ruth, Tahseen Al-Saleem, Eric M. Horwitz, Mark Sobczak, Robert G. Uzzo, Rosalia Viterbo, and Mark K. Buyyounouski

is considered moderately to poorly differentiated, and a GS of 8 through 10 is considered poorly differentiated to undifferentiated. 7 GS is an important prognostic factor, independent of initial prostate-specific antigen (PSA) level or T stage, used

Full access

Radiation Therapy Modalities in Prostate Cancer

Thomas J. Pugh, Bao-Ngoc Nguyen, James E. Kanke, Jennifer L. Johnson, and Karen E. Hoffman

undetectable prostate-specific antigen: ARO 96-02/ AUO AP 09/95 . J Clin Oncol 2009 ; 27 : 2924 – 2930 . 5 Mohler JL Armstrong AJ Bahnson RR . NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1 , 2013 . Available at: NCCN

Full access

Strategies to Circumvent Testosterone Surge and Disease Flare in Advanced Prostate Cancer: Emerging Treatment Paradigms

Venkata K. Pokuri, Houman Nourkeyhani, Bodie Betsy, Laurie Herbst, Marcus Sikorski, Edward Spangenthal, Andrew Fabiano, and Saby George

adenocarcinoma of prostatic origin and his prostate-specific antigen (PSA) level was elevated at 149 ng/mL. His local oncologist started him on bicalutamide (antiandrogen) for 2 weeks followed by a leuprolide (GnRH agonist) injection. A week after initiation of

Full access

Is Primary Androgen Deprivation Therapy a Suitable Option for Asian Patients With Prostate Cancer Compared With Radical Prostatectomy?

U-Syn Ha, Jin Bong Choi, Jung Im Shim, Minjoo Kang, Eunjung Park, Shinhee Kang, Jooyeon Park, Jangmi Yang, Insun Choi, Jeonghoon Ahn, Cheol Kwak, Chang Wook Jeong, Choung Soo Kim, Seok-Soo Byun, Seong Il Seo, Hyun Moo Lee, Seung-Ju Lee, Seung Hwan Lee, Byung Ha Chung, and Ji Youl Lee

data, but important limitations that could have affected our outcome analysis should be noted. This database does not include detailed biochemical information, such as Gleason grade and prostate-specific antigen, and therefore we could not evaluate the

Full access

Racial Differences in Germline Genetic Testing Completion Among Males With Pancreatic, Breast, or Metastatic Prostate Cancers

Jeffrey W. Shevach, Danielle Candelieri-Surette, Julie A. Lynch, Rebecca A. Hubbard, Patrick R. Alba, Karen Glanz, Ravi B. Parikh, and Kara N. Maxwell

prostate-specific antigen screening in BRCA2 mutation carriers . Eur Urol 2019 ; 76 : 831 – 842 . 12. Sawhney MS , Calderwood AH , Thosani NC , ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility

Full access

Adverse Effects of Androgen Deprivation Therapy: Defining the Problem and Promoting Health Among Men with Prostate Cancer

Philip J. Saylor and Matthew R. Smith

common clinical settings with limited data on how it impacts clinical outcomes. Two particular clinical situations lead to treatment of a large number of men. First, regular prostate-specific antigen (PSA) testing after primary therapy can diagnose PSA

Full access

NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024

Featured Updates to the NCCN Guidelines

Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Rhonda Bitting, Brian Chapin, Heather H. Cheng, Anthony Victor D’Amico, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Shilpa Gupta, Thomas Guzzo, Joseph E. Ippolito, R. Jeffrey Karnes, Michael R. Kuettel, Joshua M. Lang, Tamara Lotan, Rana R. McKay, Todd Morgan, Julio M. Pow-Sang, Robert Reiter, Mack Roach III, Tyler Robin, Stan Rosenfeld, Ahmad Shabsigh, Daniel Spratt, Russell Szmulewitz, Benjamin A. Teply, Jonathan Tward, Richard Valicenti, Jessica Karen Wong, Jenna Snedeker, and Deborah A. Freedman-Cass

Oncology (NCCN Guidelines) have, for many years, used NCCN risk groups as a framework to stratify patients with prostate cancer based on clinical and pathologic features, including T stage, prostate-specific antigen (PSA) levels, Grade Group (see “ Very

Full access

Impact of a Clinical Trial Initiative on Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic

Lydia T. Madsen, Deborah A. Kuban, Seungtaek Choi, John W. Davis, Jeri Kim, Andrew K. Lee, Delora Domain, Larry Levy, Louis L. Pisters, Curtis A. Pettaway, John F. Ward, Christopher Logothetis, and Karen E. Hoffman

, Galveston, Harris, Liberty, Montgomery, San Jacinto, and Waller counties. Prostate cancer risk group was categorized by NCCN criteria as low-risk (stage T1a-T2a, Gleason score ≤6, and prostate-specific antigen [PSA] <10 ng/mL); high-risk (stage T3-4, Gleason

Full access

Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines

James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas Farrington, Celestia S. Higano, Eric Mark Horwitz, Philip W. Kantoff, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Stan Rosenfeld, Sandy Srinivas, Seth A. Strope, Jonathan Tward, Przemyslaw Twardowski, Patrick C. Walsh, Maria Ho, and Dorothy A. Shead

especially encouraged. Overview Prostate cancer has surpassed lung cancer as the most common cancer in men. These changes may result partly from the use of serum prostate-specific antigen (PSA) for early detection of prostate cancers that may include